According to the report of the meeting of American Society of Clinical Oncology (ASCO) in 2020, among 9 patients with HNSCC who received cetuximab plus levatinib, 6 patients had a PR with 67% ORR.30 These results indicate that a combination of lenvatinib and EGFR inhibitor may have clinical benefits for different types of human cancers. This evidence concerns the gene EGFR and cancer.